Jankauskas Stanislovas S, Gambardella Jessica, Sardu Celestino, Lombardi Angela, Santulli Gaetano
Department of Medicine, Fleischer Institute for Diabetes and Metabolism (FIDAM), Einstein-Mount Sinai Diabetes Research Center (ES-DRC), Albert Einstein College of Medicine, New York, NY 10461, USA.
Department of Molecular Pharmacology, Wilf Family Cardiovascular Research Institute, Einstein Institute for Aging Research, Albert Einstein College of Medicine, New York, NY 10461, USA.
Noncoding RNA. 2021 Jul 7;7(3):39. doi: 10.3390/ncrna7030039.
Substantial evidence indicates that microRNA-155 (miR-155) plays a crucial role in the pathogenesis of diabetes mellitus (DM) and its complications. A number of clinical studies reported low serum levels of miR-155 in patients with type 2 diabetes (T2D). Preclinical studies revealed that miR-155 partakes in the phenotypic switch of cells within the islets of Langerhans under metabolic stress. Moreover, miR-155 was shown to regulate insulin sensitivity in liver, adipose tissue, and skeletal muscle. Dysregulation of miR-155 expression was also shown to predict the development of nephropathy, neuropathy, and retinopathy in DM. Here, we systematically describe the reports investigating the role of miR-155 in DM and its complications. We also discuss the recent results from and models of type 1 diabetes (T1D) and T2D, discussing the differences between clinical and preclinical studies and shedding light on the molecular pathways mediated by miR-155 in different tissues affected by DM.
大量证据表明,微小RNA-155(miR-155)在糖尿病(DM)及其并发症的发病机制中起关键作用。多项临床研究报告称,2型糖尿病(T2D)患者血清miR-155水平较低。临床前研究表明,miR-155在代谢应激下参与朗格汉斯胰岛内细胞的表型转换。此外,miR-155被证明可调节肝脏、脂肪组织和骨骼肌中的胰岛素敏感性。miR-155表达失调还被证明可预测DM患者肾病、神经病变和视网膜病变的发生。在此,我们系统地描述了有关研究miR-155在DM及其并发症中作用的报告。我们还讨论了1型糖尿病(T1D)和T2D模型的最新研究结果,探讨了临床研究和临床前研究之间的差异,并阐明了miR-155在受DM影响的不同组织中介导的分子途径。